Xeris Pharmaceuticals Inc (NASDAQ:XERS) Short Interest Increased By 33.14%

The stock of Xeris Pharmaceuticals Inc (NASDAQ:XERS) registered an increase of 33.14% in short interest. XERS’s total short interest was 944,600 shares in July as published by FINRA. Its up 33.14% from 709,500 shares, reported previously. With 396,700 shares average volume, it will take short sellers 2 days to cover their XERS’s short positions. The short interest to Xeris Pharmaceuticals Inc’s float is 7.37%.

The stock decreased 6.14% or $0.78 during the last trading session, reaching $11.93. About 236,442 shares traded or 19.32% up from the average. Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) has 0.00% since July 14, 2018 and is . It has underperformed by 4.43% the S&P500.

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. The company has market cap of $321.40 million. The Company’s proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. It currently has negative earnings. The company's lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes.

More notable recent Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) news were published by: Finance.Yahoo.com which released: “Can We See Significant Institutional Ownership On The Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Share Register? – Yahoo Finance” on May 25, 2019, also Seekingalpha.com with their article: “Stocks To Watch: Prime Time In Retail – Seeking Alpha” published on July 14, 2018, Seekingalpha.com published: “ContraVir Pharmaceuticals leads healthcare gainers; ReWalk Robotics and Bellicum Pharmaceuticals among losers – Seeking Alpha” on June 06, 2019. More interesting news about Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) were released by: Seekingalpha.com and their article: “Xeris Pharmaceuticals Is An Attractive Buy Opportunity In 2018 – Seeking Alpha” published on November 02, 2018 as well as Nasdaq.com‘s news article titled: “Is Cryptocurrency the Way to Get Millennials Investing in Real Estate Again? – Nasdaq” with publication date: November 05, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.